Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
Sponsor: Advanz Pharma
Listed as NCT00526136, this PHASE2 trial focuses on Atrial Fibrillation and remains completed. Sponsored by Advanz Pharma, it has been updated 8 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Dec 2019 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Advanz Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia, Ajka, Hungary, Amadora, Portugal, Amsterdam, Netherlands, Antwerp, Belgium, Arad, Romania, Auckland, New Zealand, Bad Krozingen, Germany, Bad Nauheim, Germany, Baja, Hungary and 109 more location s